Treatment Registry of Alecensa in Korean Patients With Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 31 Oct 2017
At a glance
- Drugs Alectinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Roche
- 25 Oct 2017 Planned initiation date changed from 15 Oct 2017 to 31 Oct 2017.
- 25 Sep 2017 Planned initiation date changed from 15 Sep 2017 to 15 Oct 2017.
- 07 Sep 2017 New trial record